UNICA IRIS Institutional Research Information System

MARONGIU, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 151.785
NA - Nord America 12.544
AS - Asia 5.317
SA - Sud America 937
Continente sconosciuto - Info sul continente non disponibili 563
AF - Africa 207
OC - Oceania 64
Totale 171.417
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 144.806
US - Stati Uniti d'America 12.281
NL - Olanda 3.819
SG - Singapore 2.002
CN - Cina 1.628
BR - Brasile 692
UA - Ucraina 677
SE - Svezia 667
VN - Vietnam 505
DE - Germania 417
GB - Regno Unito 346
FI - Finlandia 338
FR - Francia 255
HK - Hong Kong 226
BD - Bangladesh 152
IN - India 149
CA - Canada 147
KR - Corea 91
AR - Argentina 75
IQ - Iraq 70
MX - Messico 69
ZA - Sudafrica 63
RU - Federazione Russa 57
TR - Turchia 57
AU - Australia 53
JP - Giappone 53
ES - Italia 52
PK - Pakistan 50
AT - Austria 46
ID - Indonesia 44
CO - Colombia 41
IE - Irlanda 40
PL - Polonia 39
EC - Ecuador 38
IR - Iran 37
EG - Egitto 32
BE - Belgio 30
MA - Marocco 29
MY - Malesia 28
PH - Filippine 28
SA - Arabia Saudita 26
RO - Romania 25
CL - Cile 22
UZ - Uzbekistan 22
CH - Svizzera 21
VE - Venezuela 21
TN - Tunisia 19
KE - Kenya 18
PE - Perù 18
TW - Taiwan 18
HU - Ungheria 17
JO - Giordania 17
LT - Lituania 17
ET - Etiopia 15
CZ - Repubblica Ceca 14
PY - Paraguay 14
AE - Emirati Arabi Uniti 13
AL - Albania 13
TH - Thailandia 13
DK - Danimarca 12
IL - Israele 12
BG - Bulgaria 11
JM - Giamaica 11
NZ - Nuova Zelanda 11
RS - Serbia 11
KZ - Kazakistan 10
NP - Nepal 10
BA - Bosnia-Erzegovina 9
AZ - Azerbaigian 8
DZ - Algeria 8
SD - Sudan 8
CR - Costa Rica 7
GR - Grecia 7
PT - Portogallo 7
UY - Uruguay 7
BH - Bahrain 6
LB - Libano 6
PR - Porto Rico 6
CY - Cipro 5
GE - Georgia 5
NO - Norvegia 5
BO - Bolivia 4
BY - Bielorussia 4
EE - Estonia 4
MK - Macedonia 4
MT - Malta 4
CI - Costa d'Avorio 3
DO - Repubblica Dominicana 3
GT - Guatemala 3
GY - Guiana 3
HR - Croazia 3
KW - Kuwait 3
LU - Lussemburgo 3
MU - Mauritius 3
NG - Nigeria 3
OM - Oman 3
PA - Panama 3
QA - Qatar 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
Totale 170.816
Salva come PNG Salva come JPEG
Città #
Cagliari 140.521
Amsterdam 3.746
Uta 3.412
Fairfield 1.365
Ashburn 1.001
Singapore 918
Woodbridge 838
Houston 656
Chandler 641
Dallas 636
San Jose 598
Seattle 557
Wilmington 528
Boardman 513
Ann Arbor 463
Cambridge 452
Nyköping 437
Jacksonville 351
Beijing 311
Council Bluffs 310
Los Angeles 226
Helsinki 204
Hong Kong 200
The Dalles 175
Dearborn 158
Ho Chi Minh City 153
Lauterbourg 145
Santa Clara 142
New York 141
Boston 128
Shanghai 118
Nanjing 112
Hanoi 99
Buffalo 92
Hefei 88
San Diego 86
Milan 84
Seoul 73
São Paulo 62
Rome 60
Toronto 57
Dong Ket 56
Guangzhou 56
Hebei 55
Munich 52
Shenyang 49
London 47
Redwood City 46
Frankfurt am Main 45
Chicago 41
Redondo Beach 41
Changsha 37
Nanchang 36
Orem 36
Tianjin 36
Jiaxing 34
Atlanta 32
Nuremberg 32
Verona 30
Vienna 30
Baghdad 29
Brooklyn 29
Dublin 28
Brussels 27
Rio de Janeiro 27
Warsaw 27
Columbus 26
Johannesburg 26
Mexico City 26
Phoenix 25
Tokyo 24
Denver 23
Orange 23
Brandenburg 22
Millbury 22
Chennai 21
Da Nang 21
Lahore 21
Jinan 20
Norwalk 20
Stockholm 20
Tashkent 20
Haiphong 19
Manchester 19
Montreal 18
Sassari 18
Bogotá 17
Mountain View 17
San Francisco 17
Sydney 17
Turku 17
Cape Town 16
Nairobi 16
Redmond 16
Zhengzhou 16
Ankara 15
Dhaka 15
Ningbo 15
Belo Horizonte 14
Las Vegas 14
Totale 162.471
Salva come PNG Salva come JPEG
Nome #
Vaping effects on asthma: results from a web survey and clinical investigation 2.987
Sampling variability in hepatic iron concentration in beta-thalassemia 2.873
Heterogeneity of Antiphospholipid Syndrome (APS) as Characterized by Brain Perfusion Techniques. Towards New Ways of Syndrome Characterization 2.817
The venous thromboembolic risk and the clot wave analysis: a useful relationship? 2.776
Prophylaxis of peripartum haemorrhage using recombinant factor VIIa (rfVIIa) in pregnant women with congenital factor VII deficiency: A case report and literature review 2.761
Acquired factor VIII inhibitor and subsequent development of non-Hodgkin's lymphoma: a case report and review of the literature 2.587
Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment. 2.577
Olanzapine-associated portal and superior mesenteric vein thrombosis 2.524
Are prothrombin time and clot waveform analysis useful in detecting a bleeding risk in liver cirrhosis? 2.444
alpha 2 Antiplasmin and disseminated intravascular coagulation in liver cirrhosis 2.399
Telemedicine can improve the quality of oral anticoagulation using portable devices and self-testing at home 2.314
Clot wave analysis and thromboembolic score in liver cirrhosis: two opposing phenomena 2.305
A retrospective cohort study of patients with pulmonary embolism: The impact of comorbidities on patient's outcome 2.190
Empathy and the Educational Approach to Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants 2.185
Underuse of anticoagulant therapy in hospitalized older patients: comment on the article of Wojszel et al 2.171
Management of Patients Taking Oral Anticoagulants Who Need Urgent Surgery for Hip Fracture 2.158
Pulmonary Thrombosis: A Clinical Pathological Entity Distinct from Pulmonary Embolism? 2.083
Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience 2.030
Clot Waveform Analysis: From Hypercoagulability to Hypocoagulability - A Review 2.023
A Sardinian Family with Factor XI Deficiency 2.000
Ultrastructural findings of lung injury due to Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT) following COVID-19 vaccination: a scanning electron microscopic study 1.973
Vaccine-induced severe thrombotic thrombocytopenia following COVID-19 vaccination: A report of an autoptic case and review of the literature 1.910
A “Catastrophic” Heparin-Induced Thrombocytopenia 1.891
The hemostatic system. 1st Part 1.819
Points of Care Testing International Normalized Ratio: Are They Useful for Monitoring Vitamin K Antagonists in a Thrombosis Center? 1.811
Fibrinogen and D-dimer levels in autoimmune subclinical and overt hypothyroidism and effects of levothyroxine treatment. 1.792
Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review 1.759
Epidemiology of infection with HIV-1 in Sardinia: a multicentre prospective study 1.715
Point-of-care testing INR: an overview 1.685
Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? No 1.664
Uneven hepatic iron and phosphorus distribution in b-thalassemia 1.662
Pulmonary thrombosis in 2019-nCoV pneumonia? 1.660
Risk of reoperation in bioprosthetic valve patients with indication for longterm anticoagulation. Results from the observational retrospective multicentre PLECTRUM study 1.651
Optimizing tailored DIEP flap insetting in unilateral immediate free autologous breast reconstruction 1.648
Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study 1.585
Immunological aspects in anti-HIV seronegative drug addicts. Correlation with the duration of heroin addiction and other viral infections 1.578
Direct oral anticoagulants: what can we learn? 1.572
Comparison of prothrombin time INR and clot waveform analysis performed with 129-mmol/L and 105-mmol/L citrate tubes 1.565
Fatal Cytopenia Induced by Low-Dose Methotrexate in Elderly With Rheumatoid Arthritis. Identification of Risk Factors 1.516
T lymphocyte subsets and viral infections in Sardinian parenteral drug abusers: relationship to HIV infection 1.496
The criteria of the Italian Federation of Thrombosis Centres on DOACs: a ‘‘real world’’ application in nonvalvular atrial fibrillation patients already on Vitamin K Antagonist 1.490
Allele 4G of gene PAI-I associated with prothrombin mutation G20210A increases the risk for venous thrombosis 1.464
Thrombosis centres and AVKs monitoring in COVID-19 pandemic 1.450
Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules in patients on oral anticoagulants 1.394
[Immunological aspects in anti-HIV seronegative drug addicts. Correlation with the duration of heroin addiction and other viral infections]. FT Aspetti immunologici nei tossicodipendenti anti-HIV sieronegativi. Correlazione con la durata di assunzione dell'eroina e con altre infezioni virali. 1.379
Fondaparinux: Should It Be Studied in Patients with COVID-19 Disease? 1.369
Direct inhibitors of thrombin and factor Xa: the importance of laboratory skills 1.356
A guide to oral anticoagulation 1.333
Hyperhomocysteinemia: could the post-methionine oral loading test sometimes be avoided? 1.309
Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA(2)DS(2)VASc 1 or 2): a treatment dilemma 1.290
The Italian START-Register on anticoagulation with focus on atrial fibrillation 1.270
Antiphospholipid syndrome patients: The performance of Coagucheck XS in the monitoring of Vitamin K-Antagonists 1.259
Heparins and 2019-nCoV infection: a narrative review 1.249
A ‘‘two-step’’ educational approach for patients taking oral anticoagulants does not improve therapy control 1.234
Thyroid disorders and hypocoagulability 1.189
The predictive ability of bleeding risk stratification models in very old patients on vitaminK antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study 1.184
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome 1.154
Aspetti immunologici nei tossicodipendenti anti-HIV sieronegativi. Correlazione con la durata di assunzione dell’eroina e con altre infezioni virali 1.143
High frequency of inadequate test requests for antiphospholipid antibodies in daily clinical practice 1.138
Vitamin K antagonists (coumarins), drugs used in the prevention and treatment of cardioembolism, deep vein thrombosis, and pulmonary embolism 1.130
Fetal programming of atherosclerosis: may the barker hypothesis explain the susceptibility of a subset of patients to develop stroke or cardiac infarct? 1.097
Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago 1.090
A routine silica-based activated partial thromboplastin time (Hemosil aPTT-SP (TM)) mostly excludes the presence of lupus anticoagulant 1.080
Rheumatoid arthritis and thrombosis 1.080
Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA) 1.074
Fetal programming of COVID-19: May the barker hypothesis explain the susceptibility of a subset of young adults to develop severe disease? 1.018
Plasma prekallikrein (Fletcher factor) in hepatic cirrhosis 1.015
Infectious agents including COVID-19 and the involvement of blood coagulation and fibrinolysis. A narrative review 1.015
Point-of-care (POCT) prothrombin time monitors: is a periodical control of their performance useful? 1.013
Clot characterization by multidisciplinary approach: biochemical and imaging parameters in a hypocoagulative setting. A pilot study 1.003
Hemarthrosis as acute presentation of acquired hemophilia in a patient with systemic lupus erythematosus: successful treatment and long-lasting remission 998
[Short-term effect of treatment with oral DL-carnitine and intravenous L-carnitine in chronic uremia patients undergoing hemodialytic therapy]. FT Effetto a breve termine della terapia con DL-carnitina per os ed L-carnitina e.v. nei pazienti uremici cronici in trattamento emodialitico. 985
Short-term effect of treatment with oral DL-carnitine and intravenous L-carnitine in chronic uremia patients undergoing hemodialytic therapy 948
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a reply to a rebuttal 929
Center-related determinants of VKA anticoagulation quality: A prospective, multicenter evaluation 917
Thrombotic sinusoiditis and local diffuse intrasinusoidal coagulation in the liver of subjects affected by COVID-19: The evidence from histology and scanning electron microscopy 915
Aortic vulnerability to COVID-19: Is the microvasculature of vasa vasorum a key factor? A case report and a review of the literature 898
Scanning electron microscopy of lung disease due to COVID-19 – a case report and a review of the literature 849
Bleeding diathesis and gastro-duodenal ulcers in inherited cytosolic phospholipase-A2 alpha deficiency 836
Thromboembolic disease in patients with rheumatoid arthritis undergoing joint arthroplasty: Update on prophylaxes 835
Chronic intravascular coagulation in liver cirrhosis predicts a high hemorrhagic risk 835
Amoxicillina-acido clavulanico ed anticoagulanti orali:un’associazione potenzialmente pericolosa 830
Chronic spontaneous urticaria: a low-grade disseminated intravascular coagulation only partially reversed by Omalizumab 827
null 824
Start-register (Survey on anticoagulated patients register): the first year of activity 792
Clinical history and gastrointestinal bleeding in patients taking oral anticoagulants 783
null 772
Management of special conditions in patients on vitamin K antagonists 738
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 737
Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation 692
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study 684
null 679
Special indications for vitamin K antagonists: a review 677
null 644
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results 637
Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA) 636
null 633
Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2(V617F) mutation 619
null 617
null 616
Totale 141.807
Salva come PNG Salva come JPEG
Categoria #
all - tutte 242.818
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 242.818
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20228.188 0 677 410 654 750 715 606 496 695 941 1.137 1.107
2022/202313.972 1.309 1.837 1.693 1.231 1.226 1.483 702 1.112 912 789 1.042 636
2023/202416.064 668 938 777 1.394 1.606 2.190 2.415 1.091 774 1.176 1.605 1.430
2024/202528.643 6.075 7.319 3.400 2.925 3.247 1.828 2.115 175 429 432 291 407
2025/202613.770 551 369 1.237 1.019 719 609 1.735 592 4.482 1.254 720 483
2026/2027599 216 383 0 0 0 0 0 0 0 0 0 0
Totale 171.417